M eta-analyses have emerged as a useful method to summarize research findings and increase the statistical power of primary research studies. However, one of the major limitations of this form of analysis is the aggregation of trials conducted in both different populations and different clinical circumstances. This is termed clinical heterogeneity. Such clinical heterogeneity, along with other methodological limitations, may give rise to statistical heterogeneity. 1 Statistical heterogeneity occurs when estimates from individual trials vary by more than would be expected by chance which can be quantified using measures such as the I 2 statistic (0%-100%). Unexplained statistical heterogeneity can increase the uncertainty surrounding effect estimates derived from meta-analyses and reduce the quality of evidence used to BACKGROUND: Statistical heterogeneity can increase the uncertainty of results and reduce the quality of evidence derived from systematic reviews. At present, it is uncertain what the major factors are that account for heterogeneity in meta-analyses of analgesic adjuncts. Therefore, the aim of this review was to identify whether various covariates could explain statistical heterogeneity and use this to improve accuracy when reporting the efficacy of analgesics. METHODS: We searched for reviews using MEDLINE, EMBASE, CINAHL, AMED, and the Cochrane Database of Systematic Reviews. First, we identified the existence of considerable statistical heterogeneity (I 2 > 75%). Second, we conducted meta-regression analysis for the outcome of 24-hour morphine consumption using baseline risk (control group morphine consumption) and other clinical and methodological covariates. Finally, we constructed a league table of adjuvant analgesics using a novel method of reporting effect estimates assuming a fixed consumption of 50 mg postoperative morphine. RESULTS: We included 344 randomized controlled trials with 28,130 participants. Ninety-one percent of analyses showed considerable statistical heterogeneity. Baseline risk was a significant cause of between-study heterogeneity for acetaminophen, nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, tramadol, ketamine, α2-agonists, gabapentin, pregabalin, lidocaine, magnesium, and dexamethasone (R 2 = 21%-100%; P < .05). There was some evidence that the methodological limitations of the trials explained some of the residual heterogeneity. Type of surgery was not independently associated with analgesic efficacy. Assuming a fixed baseline risk of 50 mg (in order of efficacy), gabapentin, acetaminophen, α2-agonists, nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, pregabalin, tramadol, magnesium, and lidocaine demonstrated moderate clinically significant reductions (>10 mg). We could not exclude a moderate clinically significant effect with ketamine. Dexamethasone demonstrated a small clinical benefit (>5 mg). CONCLUSIONS: We empirically identified baseline morphine consumption as the major source of heterogeneity in meta-analyses of adjuvant analgesics across all surgical interventions. Controlling for baseline morphine consumption, clinicians can use audit data to estimate the morphine-reducing effect of adding any adjuvant for their local population, regardless which surgery they undergo. Moreover, we have utilized these findings to present a novel method of reporting and an amended method of graphically displaying effect estimates, which both reduces confounding from variable baseline risk in included trials and is able to adjust for other clinical and methodological confounding variables. We recommend use of these methods in clinical practice and future reviews of analgesics for postoperative pain. (Anesth Analg 2018;126:648-60) inform health care decisions. 2 In addition, in the presence of statistical heterogeneity, effect estimates may be inaccurate and lead to erroneous conclusions on the clinical significance of a particular intervention. Therefore, investigating causes for heterogeneity is essential using techniques, such as meta-regression analysis. 3 Baseline risk is a particular covariate that can help predict between-study heterogeneity in meta-analyses. For example, participants at higher risk of the condition under study (those with more pain) may derive larger absolute benefits compared to those at lower risk. However, conventional meta-regression analyses of baseline risk may be biased due to measurement error in baseline risk (x variable) and effect estimates (y variable) and the functional relationship between the 2. This causes regression to the mean, where relationships may become apparent even if none exist. 4, 5 Therefore, alternative analyses, which allow for the measurement error, such as previously developed Bayesian meta-regression models are recommended. 6 Heterogeneity is a particular problem in meta-analyses of analgesics used to prevent postoperative pain. 7 Indeed, a previous review has suggested that type of surgery should be explored in these reviews. 7 However, even within the same type of surgical procedure, pain levels and morphine consumption can be heterogeneous. In addition, differing analgesic protocols can further confound the association between type of surgery and the efficacy of the analgesic. Previous primary research has shown that the pain level experienced by a participant determines analgesic efficacy, with higher pain levels resulting in higher absolute pain score reductions following analgesic administration. 8, 9 We have previously demonstrated that using control group morphine consumption (baseline risk), we were able to explain a large degree of between-study heterogeneity, 10, 11 which may improve the quality of evidence as per Grades of Recommendation, Assessment, Development and Evaluation Group (GRADE). 2 Moreover, if baseline risk is found to explain statistical heterogeneity, any one effect estimate from a meta-analysis may be confounded by the variable baseline risk in the included trials, and, therefore, quoting meta-regression estimates from a fixed value may help reduce confounding. Therefore, our a priori hypothesis was that baseline risk and other methodological or clinical covariates could explain statistical heterogeneity in meta-analyses of analgesics. We then aimed to utilize these findings to report a novel method of presenting effect estimates using metaregression parameter estimates, which reduce confounding from variable baseline risk in the included studies. In addition, we used this novel method to produce a league table of adjuvant analgesics based on efficacy and illustrate how our novel method can better target clinical use of analgesics using local departmental audit data.
METHODS
We prospectively registered this review on the PROSPERO 12 website using the registration number CRD42016039109. Due to the numerous previous systematic reviews published on the subject, the aim of this study was to search for previous reviews of postoperative analgesics. We then identified randomized controlled trials from all included reviews and performed a secondary analysis of these ( Figure 1 ). We searched all databases from inception to May 2016: MEDLINE, EMBASE, CINAHL, AMED, and the Cochrane Database of Systematic Reviews. We used the following search terms: "postoperative AND pain," "surgery," "analgesi*," "morphine AND consumption," "opioid AND consumption," and we exploded the MeSH term "ACUTE PAIN." We combined these terms with the specific generic term for the analgesic agent. We then limited our search to reviews and meta-analyses. Figure 1 . Flowchart of included reviews. The left chart describes the initial search strategy where we identified reviews from electronic databases with 105 included in the final review. The right-hand chart describes the identification of randomized controlled trials, which were obtained from the 105 included reviews. NSAIDS indicates nonsteroidal anti-inflammatory drugs; PCA, patient-controlled analgesia.
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We extracted the data onto an electronic database. For reviews, we extracted the following data: study author, year of publication, type of agent, and methods for investigating heterogeneity. For randomized controlled trials included in the reviews, we extracted the following data: study author, year of publication, population, intervention, comparator, opioid used, risk-of-bias information, and data used to calculate effect estimates. For randomized controlled trials, to reduce selective reporting bias, if standard deviations were not reported, we estimated these from other studies in the analysis. 13 We did not attempt to estimate means and standard deviations from medians or interquartile ranges due to the high likelihood of nonnormal data. 13 If results were not reported in the text, these were estimated from published graphs.
We had no language restrictions for inclusion in our review, and we translated non-English language papers. We included reviews that included the following analgesic agents versus placebo for postoperative pain: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX) 2 inhibitors, tramadol, intravenous ketamine, α2-agonists (clonidine and dexmedetomidine), gabapentin, pregabalin, nefopam, lidocaine, magnesium, and dexamethasone. We aimed to identify reviews of prophylactic administration (defined as first dose given before the onset of pain or agents added to postoperative analgesic regimens, such as patient-controlled analgesia). We did not include reviews evaluating single-dose analgesics for established postoperative pain or reviews in dental surgery, because these are unlikely to report 24-hour morphine consumption.
The outcome of interest was 24-hour opioid consumption. We chose opioid consumption because this serves as a surrogate measure for both how painful the procedure was and any concurrent analgesia used. In addition, because participants within these trials can use variable amounts of morphine to achieve a desired level of comfort, it may be more appropriate than pain score data, which may be confounded by variable morphine use between the groups. Moreover, one of the main goals of multimodal analgesia is to reduce opioid consumption. We only included primary studies where we could extract morphine consumption data. If studies reported dosage per kilogram, we converted this to a 70-kg weight. We also used data from the day of surgery or postoperative day 1 and analyzed these as 24-hour data. If alternative opioids were reported, these were converted to morphine equivalents using the following conversion factors: oral to intravenous morphine (3:1), 14 pethidine/meperidine (10:1), 15 25 propoxyphene (10:1), 26 sublingual buprenorphine (1:25), 27 and trimeperidine (2:1). We undertook assessment of randomized controlled trials from included reviews using the Cochrane risk-of-bias tool. For blinding to receive low risk, studies had to describe in enough detail study drugs and placebos that were identical or similar in appearance rather than simply describe the study as "double-blind." 28 Outcome assessment also needed to be blinded. Attrition bias would receive high risk if patients were excluded from the analysis for reasons that may influence opioid consumption, such as those with uncontrolled pain or potential opioid adverse effects. If this information was unclear, we attempted to contact authors for further information. Studies only received low risk for selective outcome reporting if outcomes were prestated in a published protocol or trial registration referenced in the included study. Other bias included baseline characteristic imbalances, which have been associated with influencing pain (eg, sex and preoperative pain) 29 or industry sponsorship. 30 
Statistical Analysis
To quantify the degree of statistical heterogeneity, we used the I 2 statistic, with values exceeding 75% as evidence of considerable heterogeneity and those exceeding 50% as evidence of moderate statistical heterogeneity. 1 For the available data, we calculated the mean difference (MD) in morphine consumption (mg) with 95% confidence intervals (CIs) using a random-effects model. To identify whether control group morphine consumption could explain the between-study heterogeneity, we undertook meta-regression analysis. 3 This analysis is similar to conventional regression analysis, although it involves using study-level covariates, such as the dose of the analgesic used in the trial as the predictor variable and the effect estimate (MD) as the outcome variable, with each study weighted for the precision of the results (lower standard errors having more weight; Table 1 ).
We performed conventional (frequentist) meta-regression initially using control group morphine consumption (baseline risk) as a covariate based on previous findings. 10 Due to the problems with analyzing baseline risk using frequentist meta-regression, we additionally undertook Bayesian meta-regression using Markov chain Monte Carlo with Gibbs sampling following recently developed methodology that incorporates the uncertainty of the covariate estimates, which avoids the problems of regression to the mean (see Supplemental Digital Content 1, Document 1, http:// links.lww.com/AA/B813). 6 We used vague prior distributions and burnt in the Markov chain Monte Carlo chains for 10,000 iterations and then used a sample of 50,000 iterations on which to base inferences. We checked convergence visually by looking at history plots of the sampled values. We present the results of regression parameters as the median with the associated 95% credible intervals of the estimated predictive distributions.
We also used the following covariates, which we added to the frequentist model with baseline risk and present as the R 2 change from the univariate analysis using baseline risk only (Table 2) . Clinical covariates included dose or route of drug administration, type of agent (NSAIDs versus COX-2 inhibitor for example), type of surgery, and type of anesthesia. For type of surgery, where possible, we aimed to include procedure-specific evidence, if this was not possible, we grouped procedures by specialty or anatomical location. In addition, we assessed whether measures of internal validity were responsible for statistical heterogeneity including randomization, allocation concealment, blinding, and attrition bias. Except for attrition bias, these covariates were only included in models if they exaggerated effect estimates. Control group morphine consumption was initially added to the model, we then added other covariates to a multivariate model to adjust regression estimates for these confounding variables if they significantly improved the model, in a stepwise approach (P < .1 for retention in the model). Studies with missing data were excluded from the analysis.
For conventional meta-regression, we used a restricted maximum-likelihood, random-effects model. We also used the Knapp-Hartung modification as the variance estimator for effect estimates. We assessed linearity and heteroscedasticity from predicted versus residual plots, and we assessed residuals for normality using histograms. We assessed outliers from studentized residual values and leverage using the Cook distance (with values >1 regarded as a cause for concern). We present results as the proportion of betweenstudy heterogeneity explained by the model (R 2 analog) with a corresponding P value. We undertook sensitivity analysis removing studies that had significant leverage on the model and excluding studies that measured opioid consumption at other time points. We regarded P values for final models <.005 as statistically significant following Sidak adjustment for multiple comparisons.
If we identified baseline risk as a significant cause of between-study heterogeneity, we produced a league table of analgesic adjuncts based on a fixed-control group consumption of 50 mg using Bayesian parameter estimates, which aims to reduce confounding from variable baseline risk in the included trials. In addition, we constructed amended scatter plots as an alternative graphical method to Forest plots in presenting effect estimates (Figure 2 ). These plots demonstrate the relationship between baseline risk and efficacy (red regression line). These plots also show the effect estimate from a fixed consumption of 50 mg morphine (where solid horizontal red line meets the y axis) with the associated 95% CI (dashed red lines on the y axis; STATA code used to calculate effect estimates and produce amended plots in Supplemental Digital Content 2, Document 2, http://links.lww.com/AA/B814).
For results from a fixed consumption of 50 mg morphine, we regarded a difference of >20 mg as a large clinically significant difference, >10 mg a moderate clinically significant difference, and >5 mg of small clinical significance. We were unaware of any literature regarding clinically significant reductions in morphine consumption. Therefore, we selected these values based on 2 (20 mg) and 1 (10 mg) standard dose(s) of morphine. This analysis allows comparison of analgesic adjuncts when adjusted for the variable control group morphine consumption from the included randomized controlled trials to reduce confounding. However, we ranked agents based on the point estimate and did not incorporate the uncertainty around these into these ranks, and, therefore, these should be interpreted with caution. Where dose or route of administration was found to be a significant predictor, we included results from the most effective clinical situation and specified this where appropriate (for adjusted conventional estimates). We present both Bayesian parameter estimates (median) and adjusted conventional estimates with 95% CIs/CrIs.
The meta-regression parameter estimates presented in Table 1 can be used to estimate the likely reduction in 24-hour morphine consumption based on average consumption data from local departmental audits using the following formula: 
(23)
Intercepts and β-coefficients are presented for both conventional (frequentist) and Bayesian meta-regression. I 2 is the value before meta-regression and I 2res is the residual I 2 after meta-regression. Abbreviations: CI, confidence interval; COX, cyclooxygenase; CrIs, credible intervals; I 2 , measure of variability in results due to between-study differences compared to sampling variance; N/A, not applicable; NSAIDs, nonsteroidal anti-inflammatory drugs; R However, it should be noted that at extremes of baseline risk, CIs are wider and therefore the uncertainty of the estimate increases. In addition, extrapolating morphine reductions outside the limits of our models may be invalid. We did not undertake assessment for publication bias due to recent findings from our group that traditional methods may be inaccurate. We conducted all analyses using Comprehensive Meta-analysis version 3, 31 STATA version 14, 32 and WinBUGS version 1.4.
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RESULTS
We included 344 randomized controlled trials with 28, 130 participants (Table 1 and Supplemental Digital Content 3, Table 1 , http://links.lww.com/AA/B815). We identified these studies from 8 narrative reviews, 34-41 25 systematic reviews, and 72 meta-analyses 10, 11, (Figure 1 ). Of the included reviews that conducted a meta-analysis, 78% investigated heterogeneity. In 75%, investigation of heterogeneity was conducted using subgroup or sensitivity analysis and only 18% conducted meta-regression. In 32% of meta-analyses, investigation of heterogeneity was based on type of surgery, 35% used dose, and 11% used type of anesthesia. In 31% of meta-analyses, heterogeneity was investigated using methodological covariates. On risk-of-bias assessment of the individual randomized controlled trials, adequate randomization was described in 58% of studies, adequate allocation concealment in 30%, adequate blinding in 51%, and lack of attrition bias in 73%.
From the included randomized controlled trials, there was evidence of considerable statistical heterogeneity (I 2 > 75%) in most analyses (91%). On meta-regression analysis (Table 1) , control group morphine consumption (baseline risk) explained between-study heterogeneity for acetaminophen, NSAIDs and COX-2 inhibitors, tramadol, ketamine, α2-agonists, gabapentin, pregabalin, lidocaine, magnesium, and dexamethasone ( Figure 2 ). We could not analyze nefopam because we only identified 5 studies. When reanalyzed using Bayesian meta-regression, control group morphine consumption remained a significant cause of heterogeneity, and parameter estimates were very similar (Table 1) . Mean control group consumption in each meta-analysis varied between 28 and 50 mg (Table 1) . Sensitivity analyses did not change parameter estimates.
Other significant causes of between-study heterogeneity when added to the univariate model (Tables 2 and 3) included route of administration and allocation concealment for acetaminophen (R 2 = 94%; P < .001). Intravenous acetaminophen was more effective than other routes (−4 mg; 95% CI, −7.55 to −0.42 mg). For ketamine, the final model included blinding and allocation concealment, which explained the majority of the between-study heterogeneity (R 2 = 56%; P < .001). For α2-agonists, the addition of attrition bias and route of administration significantly improved the model, with intravenous (−5.4 mg; 95% CI, −11.68 to 0.89 mg) and epidural/spinal (−4.2 mg; 95% CI, −10.89 to 2.48 mg) administration (omnibus Figure 2 . The 9 amended scatterplots show for each adjuvant analgesic separately, how each study estimate (green dots) for mean morphineequivalent reduction (y axis) is linearly related to the baseline morphine consumption (x axis) in the study population (STATA code to produce this in Supplemental Digital Content 2, Document 2, http://links.lww.com/AA/B814). Diagonal red line represents the regression line and blue dotted area is the 95% confidence interval (CI). The vertical red line represents the 50 mg consumption at which to estimate the dose reduction with each adjuvant analgesic. The horizontal red line represents the effect estimate from a fixed consumption of 50 mg where these lines meet the y axis (effect estimate equivalent to the middle of the diamond on a forest plot). The dashed horizontal red lines represent the 95% CI from a fixed consumption of 50 mg (equivalent to the width of the diamond on a forest plot). A more detailed plot with the size of each study estimate representing the weight given to the study for the evidence synthesis is available on request. Results are from the frequentist meta-regression analysis. COX indicates cyclooxygenase; NSAIDS, nonsteroidal anti-inflammatory drugs.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA E META-ANALYSIS P = .07) the most effective (R 2 = 75%; P < .001). The gabapentin model was improved by the addition of perioperative dose (R 2 = 93%; P < .001). For pregabalin, the final model included allocation concealment, which significantly improved the model (R 2 = 78%; P < .001). For lidocaine, the final model included route of administration and attrition bias (R 2 = 87%; P < .001). Intravenous administration was more effective than subcutaneous patch (−6.7 mg; 95% CI, −12.62 to −0.87 mg). For magnesium, the addition of allocation concealment significantly improved the final model (R 2 = 31%; P = .008). We did not include dose, because this did not exaggerate effect estimates. Dexamethasone was the only analysis where type of surgery was a significant predictor. The final model included type of surgery and blinding (R 2 = 100%; P < .001), with larger morphine reductions in spinal and ear, nose, and throat surgery (although only based on single studies). However, analysis could not be performed with type of surgery and allocation concealment due to multicollinearity.
When assuming a fixed consumption of 50 mg postoperative morphine, we observed moderate clinically significant reductions (in order of efficacy; Figure 3 ) with gabapentin, acetaminophen, α2-agonists, NSAIDs and COX-2 inhibitors, pregabalin, tramadol, magnesium, and lidocaine. We observed small clinically significant reductions with ketamine and dexamethasone, although we could not exclude a moderate effect with ketamine based on 95% CrIs. When adjusting conventional estimates for confounders, gabapentin (1200 mg) demonstrated a large clinically significant reduction, and the results for magnesium adjusted for allocation concealment resulted in a small clinical effect (Table 3) .
DISCUSSION
We identified baseline risk as an important cause of statistical heterogeneity in meta-analyses of analgesics. We exemplified the improvement in the precision and accuracy of evidence synthesis with our proposed novel methods for several frequently used adjuvant analgesics. Our results can be used by clinicians to estimate the effects of most adjuvant analgesics in their population based on simple audit data.
In addition, we found evidence that methodological limitations explained some of the residual heterogeneity. Type of surgery did not appear to be an independent cause of between-study heterogeneity. Furthermore, our novel models have the additional advantage of being able to adjust estimates for other clinical and methodological confounding variables in the included studies.
Recent meta-analyses have attempted to explore heterogeneity using clinical covariates, such as dose and type of surgery. 115 However, these often report a low proportion of variation explained when compared to our results using baseline risk. We derived this covariate from previous empirical studies, suggesting larger reductions in pain scores following analgesic treatment with higher baseline pain scores. One study examined approximately 500 participants following dental extraction and found those with severe pain (3/3) had greater reductions in pain scores following treatment with ibuprofen compared to those with moderate pain (2/3). 8 Another study found acetaminophen and codeine treatment following cesarean delivery was only effective in those participants with severe pain (>6/10). 9 Although it should be noted that other factors in addition to degree of pain may also influence postoperative opioid consumption, such as access to patient-controlled analgesia, concurrent analgesic protocols, patient characteristics, and the prescribing practices of attending medical professionals (which may be region dependent).
A previous study of postoperative pain reviews has found widespread statistical heterogeneity and suggested that this should be explored based on type of surgery or pain scores. 7 This review recommended that future metaanalyses should include only trials from the same surgical procedures or those with close acute postoperative pain levels and explore this by using subgroup analysis. We would argue that baseline risk is a more appropriate covariate than type of surgery and meta-regression a more useful analysis than subgroup analysis because it allows reporting of the proportion of heterogeneity explained by the model (R 2 ), as well as the ability to adjust for other confounding variables. Importantly, baseline risk encompasses many Figure 3 . The forest plot of effect estimates for each analgesic in order of efficacy is based on our Bayesian meta-regression analysis and subsequent modeling for each analgesic and suggests for example, a much greater reduction in mean morphine consumption for gabapentin compared with dexamethasone. Effect size (ES) is the median and 95% credible intervals from Bayesian meta-regression estimates. x axis is the milligram reduction in morphine consumption from a fixed consumption of 50 mg. CI indicates confidence interval; COX, cyclooxygenase; NSAIDS, nonsteroidal antiinflammatory drugs. different participant and trial characteristics, such as age, sex, concurrent analgesic protocols, and other factors shown to influence postoperative morphine consumption. 137 In our previous meta-analysis with gabapentin, morphine consumption varied even within procedure-specific subgroups, and type of surgery was a small determinant of heterogeneity between studies in relation to morphine consumption and pain scores. 10 Our results suggest that expected postoperative morphine consumption (as a surrogate for pain, participant characteristics, and concurrent analgesia) is a large determinant of heterogeneity between studies.
Our results demonstrate that, with baseline risk held constant, type of surgery did not explain the differences in effect estimates in different studies for almost all adjuvant analgesics examined, meaning the adjuvant was equally effective in all surgeries. Previous groups have argued that procedure-specific evidence is necessary when evaluating evidence derived from trials of analgesic agents. 138 Our results suggest that the efficacy of analgesic agents is determined more by the degree of morphine consumption during the postoperative period rather than the type of surgery. Indeed, procedure-specific meta-analyses still suffer from considerable statistical heterogeneity. 108 Therefore, we could find little empirical basis for conducting such procedure-specific reviews for adjuvant analgesics. However, we accept that this finding contradicts both previous research and clinical intuition. We can infer from our results that evidence synthesis of analgesic adjuncts should be conducted in all forms of surgery, then type of surgery can be entered in a meta-regression model with baseline risk to see if differences exist. However, future clinical studies may be required to identify whether degree of pain is a better predictor of analgesic efficacy than type of surgery. In addition, we could not exclude an effect of type of surgery mediated via differences in baseline risk (some procedures having higher morphine consumption). Furthermore, we acknowledge that other interventions such as regional anesthesia may have more relevance to procedure-specific evidence.
When reporting the results from analgesics using a fixed consumption of postoperative morphine, we found the most effective analgesics were gabapentin, acetaminophen, α2-agonists, NSAIDs and COX-2 inhibitors, pregabalin, tramadol, magnesium, and lidocaine, all with moderate clinically significant effects. Ketamine and dexamethasone had small clinically significant effects. However, these rankings should be interpreted with caution due to the uncertainties surrounding the point estimates, which may mean analgesics lower down the table are statistically equivalent. Furthermore, efficacy is not the only consideration when considering use of these agents. Adverse effects should also be considered when selecting an analgesic agent. Agents, such acetaminophen, which have a low incidence of adverse events, may be preferable to agents that induce perioperative adverse effects such as sedation with gabapentin, especially because the differences between these agents are negligible.
In terms of the implications of our work for clinical practice, because meta-analyses are often used to inform clinical practice, reviews should present opioid reductions using a fixed consumption of morphine to more accurately reflect efficacy, because quoting the MD will be heavily influenced by the mean control morphine consumption from the included trials. In addition, indiscriminate use of analgesic adjuncts around the perioperative period should be avoided. Instead, clinicians can use information from small audits of 10 so the benefits would need to be balanced against this risk. In the instance where average reductions in morphine are 3 mg (low baseline risk) vs 20 mg (high baseline risk), a clinical decision can be made that, in the first instance, the risk may not be worth the estimated benefits. It should also be noted that at the extremes of baseline risk, CIs are wider (Figure 2) , which needs to be considered when using these estimates. CIs can be extrapolated from this figure, which at lower baseline risk may include 0 (P > .05).
In terms of randomized controlled trial design, when studying analgesic agents for postoperative pain, trials should be conducted in surgeries where expected postoperative morphine consumption is anticipated to be high. For example, for intravenous acetaminophen, where the expected postoperative morphine consumption is either 70 mg or 20 mg in the first 24 hours postoperatively, the anticipated reduction in morphine would be 26 mg and 6 mg, respectively. Relying solely on the MD (8 mg) may underestimate clinical significance in the context where postoperative morphine consumption is high. Furthermore, such larger reductions in morphine consumption may have a more pronounced effect on opioid adverse effects, 139 which have additional clinical relevance. In terms of trial conduct, as with previous studies, we have found evidence that methodological limitations, in particular, allocation concealment, were associated with larger reductions in morphine for many adjuncts. 140 Given that only a third of the included studies reported adequate allocation concealment, this is a particular area of internal validity future studies should aim to address.
In terms of secondary research studies, future meta-analyses of postoperative analgesic agents should aim to explore heterogeneity using control group morphine consumption, in addition to other sources of clinical heterogeneity such as dose or route of administration. Such explanation of statistical heterogeneity would lead to higher-quality evidence derived from these reviews as per GRADE.
2 Effect estimates from these reviews should be reported and displayed using our methods from a fixed consumption of morphine to avoid confounding by the variable baseline risk in the included primary studies (and confirmed using Bayesian analysis). To illustrate this issue using a simple example, if we take an identical intervention (gabapentin) and perform random-effects meta-analysis of the 10 studies with the lowest (MD, −1.8 mg) and highest (MD, −36.8 mg) baseline risk, we get widely disparate effect estimates.
As an extension to this, incorporating other clinical and methodological covariates into these regression models to adjust estimates can reduce further confounding. Because systematic reviews are inherently observational (despite deriving data from randomized studies), 141 more advanced and appropriate statistical methods are required (regression) that allows more accurate prediction than using MDs, while having the additional advantage of controlling for known confounders. For these reasons, future reviews of postoperative analgesics should avoid univariate subgroup analyses (due to confounding) and move toward multivariate regression models, which include control group morphine consumption (as is common practice in observational primary research studies). Future reviews could also investigate whether heterogeneity in other outcomes such as pain scores or length of stay can be explained by baseline risk. Our previous work has indicated that this may indeed be the case, 10 and other research has shown that this may apply to other outcomes such as depression. 142 Such explanation may have clinical implications, as well as allow use of the methods presented in this article to improve reporting of effect estimates.
There are several limitations with this review. First, meta-regression analysis should be regarded as observational despite deriving data from randomized studies. Such analyses are prone to both residual confounding and aggregation bias (because results are based on aggregated study estimates rather than from individual patients). For this reason, our implications for clinical practice focus on aggregated patient outcomes (from audits) rather than applying these to individual patients. Nevertheless, our models are based on studies including only a certain type of surgery or patient characteristic (from inclusion criteria), which makes extrapolation of our models to clinical circumstances outside these clinical circumstances problematic. Second, we cannot rule out type I errors in our analyses. Although conventional to set a lower level of significance to covariate adjustment in regression models (P < .1), this may also increase false-positive results.
Third, although our models can adjust for confounding variables, our analyses are limited to published primary studies and are therefore still susceptible to publication bias. Although identification of imprecise study effects is possible in systematic reviews, it is impossible to know if this is secondary to true publication bias, and, therefore, this limits our findings. Fourth, as we generally derived our studies from reviews of active versus placebo groups, we were unable to perform network meta-analysis, which may be a more appropriate method to directly compare analgesics in future reviews. Finally, we included trials from a variety of patient populations with differing clinical characteristics (comorbidity, for example), differing analgesic protocols and health care systems, which may all influence morphine consumption. 137 However, the use of a fixed consumption www.anesthesia-analgesia.org 657 of morphine should have controlled for these differences when analyzing baseline risk.
In conclusion, we have demonstrated that baseline risk (control group morphine consumption) explained a large proportion of between-study variance, and controlling for this allows pooling of heterogeneous trials in meta-analyses of adjuvant analgesics. In addition, we have shown how the use of baseline risk can allow more accurate estimation of the likely clinical benefit of analgesic adjuncts using local departmental audit data. Moreover, we have developed a novel method of presenting and an amended method of graphically displaying effect estimates, which mitigate variable baseline risk in included trials and are able to control for other confounding variables. Despite the limitations of our analysis, we recommend use of these methods in future research studies and clinical practice. E
